[Per-rectal scintigraphy of the portal system with pertechnetate TC-99M: effect of propranolol on portosystemic collateral circulation in patients with cirrhosis. Part II].
Propranolol can reduce portal hypertension, therefore is recommended in prevention of variceal bleeding in patients with liver cirrhosis. However, in certain patients with cirrhosis portal hypotensive effect of propranolol cannot be obtained, and the reason of this finding is unknown. In 28 patients with cirrhosis the effect of seven days administration of propranolol on collateral blood flow from inferior mesenteric vein was examined by means of per-rectal portal scintigraphy. Portosystemic shunt index was significantly reduced by propranolol by 17.4 +/- 4.8%. This reduction was observed in cirrhotics classified to A and B, but not C Child-Pugh. These data suggest that propranolol increases vascular resistance in portosystemic circulation which depends on severity of liver failure. This mechanism opposes reduction of portal pressure.
Bołdys
H
H
Katedry i Kliniki Gastroenterologii, Slaskiej Akademii Medycznej w Katowicach.
Hartleb
M
M
Rudzki
K
K
Nowak
A
A
Nowak
S
S
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D003097:Collateral Circulation / Q000187:drug effects*; D004932:Esophageal and Gastric Varices / Q000209:etiology / Q000517:prevention & control; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy* / Q000209:etiology; D008103:Liver Cirrhosis / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011168:Portal System / Q000000981:diagnostic imaging / Q000187:drug effects; D011433:Propranolol / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D013670:Sodium Pertechnetate Tc 99m; D014655:Vascular Resistance / Q000187:drug effects
D011433:Propranolol; D013670:Sodium Pertechnetate Tc 99m
Przezodbytnicza scyntygrafia układu wrotnego nadtechnecjanem TC-99M: wpływ propranololu na wrotno-systemowe krazenie oboczne u chorych z marskościa watroby. Cześć II.